GlobeNewswire
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
📊
AI Sentiment
Positive
7/10
Cognition Therapeutics Inc. News
Latest updates and market news for CGTX
1 news
Nov 26 - Dec 2, 2025
Page 1
Share this news page